Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors

Journal of Medical Virology

Volumn 59, Issue 4, 1999, Pages 480-490

  Cabana, Marta ^a   Clotet, Bonaventura ^a   Martínez, Miguel Angel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

HIV 1; Protease inhibitor; Reverse transcriptase

Indexed keywords

LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SEQUENCE ANALYSIS; VIRUS LOAD; VIRUS REPLICATION;

EID: 0032742698     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199912)59:4<480::AID-JMV10>3.0.CO;2-8     Document Type: Article

References (44)

1. Arnó A, Ruiz L, Juan M, Zayat MK, Puig T, Balagué M, Romeu J, Pujol R, O'Brien WA, Clotet B. 1998. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years. AIDS 12:697-704.
2. Back NK, Nijhuis M, Keulen W, Boucher CAB, Oude Essink BB, van Kuilenburg ABP, van Gennip AH, Berkhout B. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 15:4040-4049.
3. Black H, Brouwer M, Ran LJ, Wolf F, Schuitemaker H. 1998. In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J Inf Dis 177:600-610.
4. Borman AM, Paulous S, Clavel F. 1996. Resistance of HIV-1 protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol 77:419-426.
5. Carpenter CC, Fischl MA, Hammer SM, Hirsh MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. 1997. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA panel. JAMA, 25 Jun (24):1962-1969
6. CDC. 1992. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41:RR17.
7. Coffin JM. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
8. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L. 1996. Treatment of HIV infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 334:1011-1017.
9. Condra JH. 1998. Resisting resistance: maximizing the durability of antiretroviral therapy. Ann Intern Med 128:951-953.
10. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. 1997. Impaired fitness of HIV-1 variants with high-level resistance to protease inhibitors. J Virol 71:1089-1096.
11. D'Aquila RT, Hughes MD, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO. 1996. Nevirapine, zidovudine, and didanosine compared with zidovudine, and didanosine in patients with HIV-1 infection: a randomized double-blind, placebo-controlled trial - National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 124: 1019-1030.
12. Domingo E, Menendez-Arias L, Quiñones ME, Holguin A, Gutiérrez M, Martínez MA, Quer J, Novella I, Holland JJ. 1997. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog Drug Res 48:99-128.
13. Dopazo J. 1995. Windows Easy Tree software package, version 1.3 (http://www.tdi.es/programas/WET-i.html).
14. Felsenstein J. 1985. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39:783-791.
15. Felsenstein J. 1988. Phylogenies from molecular sequences: inference and reliability. Ann Rev Gen 22:521-565.
16. Felsenstein J. 1995. Phytogeny Inference Package (PHYLIP), version 3.57c. Seattle: University of Washington (http://evolution.genetics. washington.edu/phylip.html).
17. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiviral therapy. Science 278:1295-1300.
18. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz J, 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337:734-739.
19. Günthard HF, Wong JF, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, Richman DD. 1997, Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virolol 72:2422-2428.
20. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HJ, Deyton LR, Chodakewitz J, Fischl MA. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337:725-733.
21. Harrigan PR, Kinghorn I, Bloor S, Kemp SD, Najera I, Kohli A, Larder BA. 1996. Significance of amino acid variation at HIV-1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 68:2016-2020.
22. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, Hellmann NS, Bandrapalli NI, Digilio L, Branson B, Kahn JO. 1998. Sexual transmission of an HIV-1 variant resistant to multiple reverae-transcriptase and protease inhibitors N Engl J Med 339:307-311.
23. Hertogs K, Béthune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, Pauwels R. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombianant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemotherapy 42:269-276.
24. Jong JJ, Jurriaans S, Goudsmit J, et al. 1998. Insertion of two amino acids in reverse transcriptase (RT) during antiretroviral combination therapy: implications for resistance against nucleoside RT inhibitors. In Program and abstracts of the 2nd International Workshop on HIV Drug resistances and Treatment Strategies, Lake Maggiore, Italy.
25. Kaufmann D, Pantaleo G, Sudre P, Talenti A. 1998. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 351:723-724.
26. Kavlick MF, Wyvill K, Yarchoan R, Mitsuya H. 1998. Emergence of multi-dideoxynucleoside-resistant HIV-1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J Inf Dis 177:1506-1513.
27. Larder BA, Kemp SD, Harrigan PR. 1995. Potencial mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
28. Leigh-Brown A. 1997. Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Nat Acad Sci USA 94:1862-1865.
29. Leigh-Brown A, Richman DD. 1997. HIV-1 gambling on the evolution of drug resistance. Nat Med 3:268-271.
30. Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, Ho DD. 1995. Selection and analysis of HIV-1 variants with increase resistance to ABT-538, a novel protease inhibitor. J Virol 69:701-706.
31. Martínez MA, Cabana M, Ibäñez A, Clotet B, Arnó A, Ruiz L. 1999. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 256:180-187.
32. Martínez-Picado J, Savara A, Sutton L, D'Aquila RT. 1999. Replicative fitness of protease inhibitor-resistant mutants of Human Immunodeficiency Virus type 1. J Virol 73:3744-3752.
33. Myers G, Foley B, Mellors JW, Korber B, Jeang KT, Wain-Hobson S. 1996. Human retroviruses and AIDS database 1996. Los Alamos, NM: Theoretical Biology, Los Alamos National Laboratory.
34. Nijhuis M, Schurman R, Jong DD, Schipper P, Danner S, Boucher C. 1997. Selection of HIV-1 variants with increase fitness during ritonavir therapy. In Program and abstracts of the 1st International Workshop on HIV Drug Resistances and Treatment Strategies. St Petersbourg.
35. Page RDM. 1996. TREEVIEW: an application to display phylogenetic trees on personal computers. Comp Applied Biosci 12:53-60.
36. Perrin L, Talenti A. 1998. HIV treatment failure: testing for HIV resistance in clinical practice. Science 280:1871-1873.
37. Quiñones-Mateu ME, Albright JL, Mas A, Soriano V, Arts EJ. 1998. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with Group O strains of human immunodeficiency virus type 1. J Virol 72:9002-9015.
38. Rose RE, Gong YF, Greytok JA, Bechtold CM, Terry BJ, Robinson BS, Alam M, Colonno RJ, Lin PF. 1997. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Nat Acad Sci USA 93:1648-1653.
39. Schmit JC, Cogniaux J, Hermans P, Van Vaeck C, Sprecher S, Van Remoortel B, Witvrouw M, Balzarini J, Desmyter J, De Clercq E, Vandamme AM. 1996. Multiple drug resistance to nucleoside analoges and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating HIV-1 patient strain. J Inf Dis 174:962-968.
40. Shafer RW, Winters MA, Palmer S, Merigan TC. 1998. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 128:906-911.
41. Sharma PL, Crumpacker CS. 1997. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol 71:8846-8851.
42. Whitcomb JM, Limoli K, Wrin T, Smith D, Tian H, Parkin N, Lie YS, Petropoulus CJ. 1998. Phenotypic and genotypic analysis of stavudine-resistant isolates of HIV-1. In Program and abstracts of the 2nd International Workshop on HIV Drug Resistances and Treatment Strategies. Lake Maggiore, Italy.
43. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Katzenstein DA, Shafer RW, Merigan T. 1998. Phenotipic and molecular analysis of HIV-1 isolates possessing 6 bp inserts in the reverse transcriptase gene that confer resistance to nucleoside analogues. In Program and abstracts of the 2nd International Workshop on HIV Drug Resistances and Treatment Strategies. Lake Maggiore, Italy.
44. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295.